Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALXN2220 · 2 trials · 2 indications
To evaluate the long-term safety and tolerability of ALXN2220 in participants with ATTR-CM
| Arm | Type | Description |
|---|---|---|
| ALXN2220 | EXPERIMENTAL | Eligible participants will receive ALXN2220 administered IV q4w for a minimum of 12 months and up to 24 months or until participant has access to commercially available ALXN2220 for ATTR-CM, whichever occurs first. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo via IV infusion q4w for at least 30 months up to a maximum of 48 months. |
| Name | Type | Description |
|---|---|---|
| ALXN2220 | DRUG | To be administered as an IV infusion |
| Placebo | DRUG | Participants will receive placebo via IV infusion. |
* Inclusion Criteria * Type of Participant: Participants who have completed the Blinded Treatment Period (including the PC visit) of Study 301. * Sex and Contraceptive/Barrier Requirements: Male and/or female (according to their reproductive organs and functions assigned by chromosomal complement). ...
ALXN2220 is an investigational small molecule being developed for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), a condition in which abnormal protein deposits accumulate in the heart. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities.
ALXN2220 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The drug is currently in Phase 3 clinical trials for transthyretin amyloid cardiomyopathy.
ALXN2220 is in Phase 3 clinical development. It is being studied in two Phase 3 trials for transthyretin amyloid cardiomyopathy, including a placebo-controlled study and an open-label long-term safety and efficacy study. The drug is investigational and not yet approved.
ALXN2220 is being evaluated in two Phase 3 trials. NCT06183931 is a randomized, double-blind, placebo-controlled study in adults with ATTR-CM, enrolling 1181 participants. NCT07789483 is an open-label study assessing long-term safety and efficacy, with a planned enrollment of 1180 participants.
ALXN2220 is the primary name for this investigational drug. No alternative names have been reported for this compound, which is being developed by AstraZeneca for transthyretin amyloid cardiomyopathy.